Search research articles
Contact Us
Filters
Showing results (771-780 of 781) with videos related to
Page
of 79
Sort By:
Nature Communications
|
January 7, 2026
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial
Dalong Zhu, Weimin Wang, Guoyu Tong, et al.
BMC Infectious Diseases
|
March 1, 2014
Enhanced surveillance of acute flaccid paralysis following importation of wild poliovirus in Xinjiang Uygur Autonomous Region, China
Ning Wen, Chun-Xiang Fan, Jian-Ping Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2015
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma
Mark W Clemens, L Jeffrey Medeiros, Charles E Butler, et al.
American Journal of Hematology
|
December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality
Abhishek Maiti, Wei Qiao, Koji Sasaki, et al.
Journal of the American Medical Directors Association
|
July 6, 2017
Attitudes Toward Advance Directives Among Patients and Their Family Members in China
Lin Kang, Xiao-Hong Liu, Jing Zhang, et al.
Nature Communications
|
October 19, 2021
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy
Hussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.
Blood Advances
|
April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia
Abhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
Molecular Cancer
|
October 15, 2025
Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth
Aleksandra Fesiuk, Daniel Pölöske, Elvin D de Araujo, et al.
The Lancet. Haematology
|
September 8, 2020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, et al.
Page
of 79
Search research articles
Search
Showing results (771-780 of 781) with videos related to
Sort By:
Page
of 79
Nature Communications
|
January 7, 2026
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial
Dalong Zhu, Weimin Wang, Guoyu Tong, et al.
BMC Infectious Diseases
|
March 1, 2014
Enhanced surveillance of acute flaccid paralysis following importation of wild poliovirus in Xinjiang Uygur Autonomous Region, China
Ning Wen, Chun-Xiang Fan, Jian-Ping Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2015
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma
Mark W Clemens, L Jeffrey Medeiros, Charles E Butler, et al.
American Journal of Hematology
|
December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality
Abhishek Maiti, Wei Qiao, Koji Sasaki, et al.
Journal of the American Medical Directors Association
|
July 6, 2017
Attitudes Toward Advance Directives Among Patients and Their Family Members in China
Lin Kang, Xiao-Hong Liu, Jing Zhang, et al.
Nature Communications
|
October 19, 2021
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy
Hussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.
Blood Advances
|
April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia
Abhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
Molecular Cancer
|
October 15, 2025
Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth
Aleksandra Fesiuk, Daniel Pölöske, Elvin D de Araujo, et al.
The Lancet. Haematology
|
September 8, 2020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, et al.
Page
of 79